From "blockbusters" to "biosimilars": An opportunity for patients, medical specialists and health care providers

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 6, 2012, Pages 483-486

  Braido, F ^a   Holgate, S ^b   Canonica, G W ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asthma; Biosimilars; Biotech

Indexed keywords

ALPHA2A INTERFERON; BIOSIMILAR AGENT; ERYTHROPOIETIN; GENERIC DRUG; GROWTH HORMONE; INSULIN; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PEGYLATED THROMBOPOIETIN; POLYSORBATE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RESLIZUMAB; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ALLERGY; ARTICLE; ASTHMA; BIOTECHNOLOGICAL PRODUCTION; COST; COST CONTROL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH CARE PERSONNEL; HUMAN; IMMUNOGENICITY; LICENCE; MEDICAL SPECIALIST; PATENT; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROCESSING; SYRINGE; THROMBOCYTOPENIA;

BIOLOGICAL AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG DESIGN; DRUG INDUSTRY; DRUG MONITORING; DRUGS, GENERIC; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC;

EID: 84870250388     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.09.005     Document Type: Article

References (30)

1. Baiardini I., Braido F., Bonini M., Compalati E., Canonica G.W. Why do doctors and patients not follow guidelines?. Curr Opin Allergy Clin Immunol 2009, 9:228-233.
2. PhRMA, CMR, Genentech, Booz, Allen Haneton: The global innovation 1000; 2006.
3. Lessons from Lipitor and the broken blockbuster drug model. Lancet 2011, 378. 1976.
4. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010 Jul 22, 363:301-304.
5. http://www.healthsciencestrategy.com.
6. Giezen T.J., Mantel-Teeuwisse A.K., Straus S.M., Schellekens H., Leufkens H.G., Egberts A.C. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Assoc 2008, 300:1887-1896.
7. EvaluatePharma® World Preview to 2012; 6 June 2008.
8. Nature medicine. News 04 May 2012, 18:636. [Published online].
9. http://www.ema.europa.eu.
10. http://www.fda.gov.
11. Roger S.D. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010, 10:1011-1018.
12. Oberg K., Alm G. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 1997, 10:1-5.
13. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007, 30:267-272.
14. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
15. Schellekens H. Biosimilar epoetins: how similar are they?. Eur J Hosp Pharm 2004, 3:8-12.
16. Mellstedt H., Niederwieser D., Ludwig H. The challenge of biosimilars. Ann Oncol 2008, 19:411-419.
17. Locatelli F., Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006, 21 Suppl 5:v13-6.
18. Duerden M. Prescribing advice needed for new biosimilar biological drugs. Prescriber 2007, 18. 7-2.
19. Roger S.D., Goldsmith D. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008, 33:459-464.
20. Haussler B. Cost savings potential of biosimilars in the German health care system. Life science in the capital market biosimilars 2010, DVFA.
21. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J Allergy Clin Immunol 2007, 120:1269-1275.
22. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
23. Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin e antibody, on airway wall thickening in asthma. Respiration 2012, 83:520-528.
24. Riccio A.M., Dal Negro R.W., Micheletto C., De Ferrari L., Folli C., Chiappori A., et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patient. Int J Immunopathol Pharmacol 2012, 25:475-484.
25. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
26. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
27. Castro M., Mathur S., Hargreave F., Boulet L.P., Xie F., Young J., Res-5-0010 Study Group, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:112.
28. Barnes P.J. New therapies for asthma: is there any progress?. Trends Pharmacol Sci 2010, 31:335-343.
29. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
30. Calderón M.A., Casale T.B., Togias A., Bousquet J., Durham S.R., Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011, 127:30-38.